Company news

Shanghai Allist Pharmaceuticals Co. Ltd. news in 2026

Shanghai Allist Pharmaceuticals Co. Ltd.'s news releases, calls and decks from 2026, newest first.

View company

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Voluntary Disclosure of the Inclusion of Furmonertinib Mesilate Tablets for Indications in the Second-line Treatment of EGFR Exon 20 Insertion Mutant NSCLC in the National Reimbursement Drug List

November 15, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Voluntary Disclosure of Receipt of the Drug Clinical Trial Approval Notice for AST1001 for Injection

November 6, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Progress in the Arbitration Matters

November 4, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction

November 3, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Resignation of Board Secretary and Designation of the Chairman to Act as the Board Secretary

November 2, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Progress in Repurchasing Shares through Call Auction

November 2, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Report for Q3 2026

October 27, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Voluntary Disclosure of FDA Approval of the Clinical Trial Application for AST1001 for Injection

October 23, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase

October 20, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Initial Repurchase of Shares through Call Auction

October 19, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Share Repurchase Plan through Call Auction

October 13, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Resolutions of the 5th Meeting of the 3rd Board of Directors

October 13, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Proposal by the Actual Controller, Chairman and General Manager to Repurchase Company Shares

October 7, 2026

(688578)"SHANGHAI ALLIST PHARMACEUTICALS CO., LTD."Announcement on Progress of the Pivotal Clinical Trial of Furmonertinib for First-line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations

October 7, 2026

Announcement on Voluntary Disclosure of the Acceptance of Marketing Application for a New Indication of Furmonertinib Mesilate Tablets

September 21, 2026

Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry

September 7, 2026

Announcement on Implementation of Dividend Distribution for the First Half of 2026

August 26, 2026

Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026

August 19, 2026

Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

July 16, 2026

Announcement on Abnormal Fluctuations in Stock Trading

July 3, 2026

Announcement on Implementation of Dividend Distribution for 2025

May 25, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 13, 2026

Announcement on Voluntary Disclosure of Obtaining of Approval Notice for the Drug Clinical Trial of Newly Approved Indication of Furmonertinib Mesylate Tablets

April 29, 2026

Notice on Convening the 2025 Annual General Meeting

April 22, 2026

Announcement on Convening Performance and Cash Dividend Briefing for 2025 and Q1 2026

April 20, 2026

Announcement on Voluntary Disclosure of Earnings Preannouncement for Q1 2026

March 3, 2026

Announcement on Preliminary Earnings Estimate for 2025

February 26, 2026

Announcement on Voluntary Disclosure of Progress in Drug Registration for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

February 3, 2026

Announcement on Expected Increase in Performance for 2025

January 28, 2026